Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-806-1074
Debt
Current Ratio19.91
Quick Ratio19.91
Price-To-Earnings
Sales & Book Value
Annual Sales$4.49 million
Price / Sales32.19
Price / Cash FlowN/A
Price / Book0.61
Profitability
Net Income$-70,980,000.00
Net Margins-1,752.41%
Return on Assets-34.61%
Miscellaneous
Employees82
OptionableOptionable
Chimerix (NASDAQ:CMRX) Frequently Asked Questions
What is Chimerix's stock symbol?
Chimerix trades on the NASDAQ under the ticker symbol "CMRX."
How were Chimerix's earnings last quarter?
Chimerix Inc (NASDAQ:CMRX) released its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.09. The biopharmaceutical company earned $0.37 million during the quarter, compared to analyst estimates of $0.97 million. Chimerix had a negative return on equity of 36.40% and a negative net margin of 1,752.41%. View Chimerix's Earnings History.
When is Chimerix's next earnings date?
What price target have analysts set for CMRX?
3 Wall Street analysts have issued 12 month target prices for Chimerix's stock. Their predictions range from $6.00 to $10.00. On average, they expect Chimerix's stock price to reach $8.00 in the next year. This suggests a possible upside of 175.9% from the stock's current price. View Analyst Price Targets for Chimerix.
What is the consensus analysts' recommendation for Chimerix?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chimerix.
What are Wall Street analysts saying about Chimerix stock?
Here are some recent quotes from research analysts about Chimerix stock:
- 1. According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (1/16/2019)
- 2. HC Wainwright analysts commented, "We base our $10 price target on probability-adjusted revenue forecasts for brincidofovir in AdV, smallpox and multiviral prevention. We use the net present value of our revenue forecast through 2026, apply a 15% POS for brincidofovir in AdV and other viruses, a 35% POS for brincidofovir in smallpox, a 4x price/sales multiple, value the early stage pipeline at $1.56/share and 2Q18 fully diluted net cash of $4.08/share to arrive at our $10 price target. Our P/S multiple of 4x is in line with Chimerix’s peers that range between 2-5x." (9/7/2018)
Has Chimerix been receiving favorable news coverage?
Media stories about CMRX stock have been trending positive recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Chimerix earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the stock's share price in the next few days.
Are investors shorting Chimerix?
Chimerix saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 373,932 shares, a drop of 40.1% from the December 14th total of 623,801 shares. Based on an average trading volume of 699,283 shares, the short-interest ratio is presently 0.5 days. Approximately 0.8% of the company's shares are short sold. View Chimerix's Current Options Chain.
Who are some of Chimerix's key competitors?
Some companies that are related to Chimerix include ChemoCentryx (CCXI), Viking Therapeutics (VKTX), Karyopharm Therapeutics (KPTI), Aptinyx (APTX), Cara Therapeutics (CARA), ProQR Therapeutics (PRQR), MacroGenics (MGNX), AMAG Pharmaceuticals (AMAG), Crinetics Pharmaceuticals (CRNX), CymaBay Therapeutics (CBAY), Assembly Biosciences (ASMB), Flexion Therapeutics (FLXN), Arvinas (ARVN), Collegium Pharmaceutical (COLL) and Zymeworks (ZYME).
Who are Chimerix's key executives?
Chimerix's management team includes the folowing people:
- M. Michelle Berrey, President, Chief Executive Officer & Director
- Timothy W. Trost, Chief Financial Officer, Secretary & Senior VP
- Randall Lanier, Chief Science Officer
- Roy W. Ware, Chief Technology & Manufacturing Officer
- Joseph F. Rutledge, Chief Information Officer & VP-IT
How do I buy shares of Chimerix?
Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chimerix's stock price today?
One share of CMRX stock can currently be purchased for approximately $2.90.
How big of a company is Chimerix?
Chimerix has a market capitalization of $153.69 million and generates $4.49 million in revenue each year. The biopharmaceutical company earns $-70,980,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Chimerix employs 82 workers across the globe.
What is Chimerix's official website?
How can I contact Chimerix?
Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]
MarketBeat Community Rating for Chimerix (NASDAQ CMRX)
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe CMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
